I mmunostimulators, as adjuvant therapeutic agents for the treatment of many tumors and infectious diseases such as the AIDS epidemic, have aroused great attention due to their highly potential value to enhance the ability of the human immune system. 1 Many different compounds, such as biological macromolecules, including glycoproteins, 2 polynucleotides, 3 and polysaccharides, 4 and small molecules, including heterocycles, 5 nucleosides, 6 glycosylceramides (glycolipids), 7 and iminosugars, 8 have been demonstrated to possess immunostimulatory properties. Some of them have been applied in the clinic as immunoadjuvants or immunomodulating drugs, such as interferon, 2 β-glucan, 4 levamisole, 9 and pidotimod 10 ( Figure 1A , B), and so on. However, the drawbacks, including side-effects, low titer, and high cost, limited their widely applications in clinical trails. 11 It is still of great interest and challenge to explore more effective and safe immunostimulants for treating immunologic disorders.
Nucleoside-based small molecule immunostimulants that affect the proliferation and potentiation of the cytokine-producing humoral cells have offered considerable promise in drug development. 6 Among them, the guanosine derivatives (e.g., Loxoribine, Figure 1D ) have been extensively studied and proved to hold potential as immunostimulating agents.
12 Nonclassic base-modified nucleosides represent a large group of pseudonucleosides in which the natural pyrimidine or purine base was replaced by heterocycles such as thiazole, imidazole, triazole, triazine, etc. 13 However, such nucleoside analogues are scarcely explored for their immunomodulating activity, although they have been well documented as promising anti-infective and antitumor agents. 14, 15 The thiazolidin-4-one ring is a core substructure in various synthetic pharmaceuticals which are associated with diverse biological activities, 16 such as anticancer, antiviral, and antiinflammatory, and some thiazolidine derivatives; for instance, levamisole, pidotimod, and CGP52608 ( Figure 1C ) 17 exhibited strong immunostimulating activities. More recently, we have found that the thiazolidin-4-one linked pseudodisaccharides ( Figure 1E ) showed very good immunostimulatng activity, 18 which prompted us to develop the novel C-pseudonucleosides having a thiazolidin-4-one moiety for investigating their immune activity. Herein, as the continuation of our studies on functionalized nucleoside analogues, 19 we would like to report a simple and convenient synthesis of novel C-pseudonucleosides bearing thiazolidin-4-one (4 and 5) by one-pot, three-component condensation from the unprotected sugar aldehyde 1 (Scheme 1), and their biological effects on T cells, B cells, and the cytokine secretion of IL-2, IL-4, and IFN-γ from mouse splenocytes. Furthermore, the effects on the membrane expression of T cellassociated molecules (CD3, CD4, CD8) and B cell-associated molecules (CD19) were also investigated.
The requisite sugar aldehyde 1 has been readily prepared in one step from D-glucosamine hydrochloride in the high yield of 85%. 20 The C-pseudonucleosides 4 and 5 were synthesized by one-pot, three-component condensation from the unprotected sugar aldehyde 1, aliphatic primary amines or anilines 2aÀe, and mercaptoacetic acid 3 at room temperature, as shown in Scheme 1. The one-pot synthesis, following our reported precedure, 19 but without using the condensation reagent N,N 0 -dicyclohexylcarbodiimide ABSTRACT: Several novel C-pseudonucleosides bearing thiazolidin-4-one were synthesized by one-pot three-component condensation using unprotected sugar aldehyde at room temperature, and their effects on T cells, B cells, the cytokine secretion of IL-2, IL-4, and IFN-γ, T cell-associated molecules (CD3, CD4, CD8), and B cell-associated molecules (CD19) were first evaluated. The experimental data demonstrated that such thiazolidin-4-one C-pseudonucleosides hold potential as immunostimulating agents.
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LETTER (DCC) and the promoter 4-dimethylaminopryidine (DMAP), directly afforded the diastereomeric products 4 (less polar) and 5 (more polar), respectively, in the overall yields of 36À43%, after simple working up and purification by reverse silica (C 18 ) gel column chromatography. This modified reaction provided a more direct, simple, and efficient access to the target C-pseudonucleosides containing thiazolidin-4-one using the unprotected sugar aldehyde, although the yields in the condensation step were moderate compared to those reported, 21, 22 in which the protected sugars were used and a deprotection must be done to give the target molecules.
The structures of the C-pseudonucleosides 4 and 5 were assigned on the basis of the analyses of their spectral data of NMR and HRMS(ESI) (see the Supporting Information). The X-ray crystallographic analysis of compound 5a indicated that the configuration of the new generated chiral carbon (C-2) is in the (R) form. Accordingly, its diastereomer 4a should have the (S) form. The circular dichroism (CD) spectra of compounds 4 showed positive Cotton effects nearly at 230 nm and negative Cotton effects at 205 nm, while 5 showed opposite Cotton effects at the corresponding regions, providing a further support to the configurations of C-2 in the diastereomers 4 (S) and 5 (R).
The effects of the C-pseodonucleosides 4 and 5 on the concavalin A (Con A)-induced proliferation of mouse splenocyte were assessed by the MTT method. The cells were harvested after 72 h incubation at 37°C, 5% CO 2 . As shown in Figure 2 , compounds 4a, 5a, 4e, and 5e promoted Con A-induced T cell proliferation significantly at certain concentrations. Compared to the Con A-treated sample, the treatment with the combination of Con A and 4a (5, 10, 25, 50, and 100 μM) increased the proliferation by 28, 290, 138, 35, and 245%, respectively, and the concentration dependence was not obvious. Compound 5a (5, 10, 25, 50, and 100 μM) also increased the Con A-induced cell proliferation irregularly by 111, 98, 91, 327, and 230%, respectively. Similarly concentration-independent phenomena were also found in compounds 4e and 5e, which showed the most pronounced effects on T cell proliferation, at 5 and at 50 μM, respectively. However, the other compounds, 4b, 5b, 4c, 5c, 4d, and 5d, did not express significant effects on T cells proliferation at the tested concentrations, and all the proliferation rates were below 50% (not shown). The results suggested that the immunostimulating activity decreased with the elongation of the alkyl chain on the N-3 position at the thiazolindin-4-one ring. In addition, the similar activity of the diastereomeric compounds 4a and 5a (or 4e and 5e) implied that the configurations in C-2 did not have significant effects on their immunostimulatory activity.
In the absence of Con A, compounds 4a, 5a, 4e, and 5e could not induce cell proliferation, implying that the compounds synergistically induced the immune response with Con A. Next we assayed the effects of these four compounds on the secretion of various cytokines in the culture of total splenocytes. Using a mice ELISA kit, the levels of the cytokines, such as interleukin-4 (IL-4), IL-2, and interferon-γ (IFN-γ), were measured from the supernatant of cell cultures in the presence of Con A (20 μM) in combination with the compounds synthesized above. Compounds 4a, 5a, and 4e at their optimized effective concentrations of 10, 50, and 5 μM were tested respectively. Since 5e at 5 μM (166%) and 50 μM (171%) demonstrated similar effects on Con A-induced cell proliferation, 5 μM of 5e were tested.
Compared with Con A alone, a combination of Con A and 4a, 5a, 4e, or 5e increased the levels of IL-4 secretion by 43, 42, 39, and 41% (p < 0.001), respectively (Figure 3 A) , which indicated that the compounds had similar proliferation effects on IL-4. With regard to IFN-γ, compounds 4a and 5a obviously increased the secretion levels of this cytokine by 21 and 30% (p < 0.001), respectively, while compounds 4e and 5e had no effects on IFN-γ secretion ( Figure 3B ). Compounds 4a, 4e, and 5e also markedly induced the secretion levels of IL-2 by 78, 99, and 138% (p < 0.001), respectively, and compound 5a increased slightly the IL-2 level by 37% ( Figure 3C ). Clearly, compounds 4e and 5e had more pronounced effects on IL-2 secretion than compounds 4a and 5a. The effects of the compounds on the T cells expressing CD3, CD4, and CD8 and on the B cells expressing CD19 were assayed by the flow cytometer (FCM). 23 Compared to the Con A-treated cells, the four compounds 4a, 5a, 4e, and 5e had proliferative effects on CD3+T cells and CD4+T cells (Figure 4A, B) . However, they had no effects on CD8+T cells ( Figure 4C ). On the other hand, compounds 4e and 5e demonstrated stronger proliferative effects on the CD19+B cell population than compounds 4a and 5a did ( Figure 4D ), which indicated that compounds 4e and 5e preferred to promote B cell proliferation more than compounds 4a and 5a ( Figure 5 , compounds 4e and 5e at 5 μM increased the LPS-induced cell proliferation by 117 and 238%, respectively). These observations suggested that the C-nucleosides 4a and 5a had potentials in proliferative effects on the CD4+T cells, and compounds 4e and 5e specifically stimulated the proliferation of both CD4+T cells and B cells.
CD4+T cells which recognize the antigen peptide and MHC II complex include T helper type 1 and 2 (T H1 and T H2 ) cells. T H1 cells secrete IFN-γ and IL-2, while T H2 cells secrete IL-4. IL-4, the hallmark cytokine of the T H2 cells, stimulates B cells to secrete antibodies and improves the proliferation and differentiation of T-cells as a key regulator in humoral and adaptive immunity.
24 IL-2 secreted by the T H1 cells is instrumental in the body's natural response to microbial infection. IFN-γ, the hallmark cytokine of the T H1 cells, shows antiviral, immunoregulatory, and antitumor properties and is used to treat infectious diseases, although it may precipitate autoimmunity. The imbalance between T H1 and T H2 cytokines is closely related with the outcome of many diseases. T H1 responses predominate in organspecific autoimmune disorders, in acute allograft rejection, and in some chronic inflammatory disorders. In contrast, T H2 responses predominate in Omann's syndrome, transplantation tolerance, chronic graft-versus-host disease, systemic sclerosis, and allergic diseases.
Compounds 4a and 5a (R = CH 3 ) had a significant capability to augment all of the secretions of IL-4, IFN-γ, and IL-2. Therefore, they might have immunopotentiating efficiency via both T H1 -and T H2 -mediated cellular as well as humoral immune activation. On the other hand, compounds 4e and 5e (R = phenyl) increased IL-4 and IL-2 secretions and inhibited IFN-γ, which indicated that they might have a bias via T H2 -mediated cellular immunity. Furthermore, compounds 4a and 5a specifically promoted CD3+ and CD4+T cell proliferation, while compounds 4e and 5e could enhance the proliferation of CD3+, CD4+T, and B cells. The results would suggeste that (1) such C-pseudonucleosides bearing thiazolidine-4-ones 4a, 5a, 4e, and 5e were good immunostimulators in controlling infection and triggering the response to antibodies and (2) the difference of the substituent at N-3 on the thiazolindin-4-one ring would lead to different mechanisms for the compounds to proliferate different cells, possibly due to the different structural regions.
In conclusion, we have reported a simple and convenient synthesis of C-pseudonucleosides bearing thiazolidin-4-one as base from the unprotected sugar aldehyde, aliphatic and alkyl primary amines, and mercaptoacetic acid at room temperature. Biological tests revealed that compounds 4a, 5a, 4e, and 5e had significant effects on T cell proliferation at certain concentrations. The preliminary structureÀactivity relationship (SAR) analysis indicated that the configuration difference in C-2 between 4 (S) and 5 (R) had little effect on their immunostimulating activity, and as the alkyl chain on the N-3 position at the thiazolindin-4-one ring lengthened, the immunostimulating activity reduced. Given that the compounds act synergistically with the mitogen Con A, they may be suitable adjuvants with immunboosting drugs and vaccines. 
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The financial supports from the National Basic Research 973 Program of China (2010CB534913), the National Natural Science Figure 4 . Proliferative effects on CD3+ (A), CD4+ (B), CD8+ (C), and CD19+ (D) cells of compounds 4a, 5a, 4e, and 5e with the concentration of 10, 50, 5, and 5 μM, respectively. Data are means ( SEM of at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001. Figure 5 . Effects of compounds 4a, 5a, 4e, and 5e on 10 μg/mL LPSinduced splenocyte proliferation. The concentrations of compounds were 10, 50, 5, and 5 μM, respectively. Data are means ( SEM of at least three independent experiments. # p < 0.01 with respect to the untreated cells; *p < 0.05, **p < 0.01, ***p < 0.001 with respect to the LPStreated cells.
